acquired
Stage
1
Investors
About
Dice Therapeutics is a clinical-stage biotechnology company focused on developing innovative medicines in immunology and oncology. The company went public in 2021 under NASDAQ:DICE and was later acquired by Eli Lilly.
Explore Dice Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.